One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19?
J.M.Martin-Moreno1S.Lessof2
Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: lessons from the PEARL study
E.Agostinetto12M.Ignatiadis1
Postoperative ctDNA monitoring: a canary in a coalmine
M.A.Lumish12N.Tarazona34Y.Y.Janjigian12
Adjuvant imatinib for GIST: duration likely matters
M.Eriksson1H.Joensuu2
Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
E.Baudin1M.Caplin2R.Garcia-Carbonero3N.Fazio4P.Ferolla5P.L.Filosso6A.Frilling7W.W.de Herder8D.Hörsch9U.Knigge10C.M.Korse11E.Lim12C.Lombard-Bohas13M.Pavel14J.Y.Scoazec15A.Sundin16A.Berruti17ESMO Guidelines Committee
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upâ€
P.Bossi1‡A.T.Chan2‡L.Licitra3A.Trama4E.Orlandi5E.P.Hui2J.Halámková6S.Mattheis7B.Baujat8J.Hardillo9L.Smeele10C.van Herpen11A.Castro12J.-P.Machiels1314ESMO Guidelines CommitteeEURACAN
Exosome-based liquid biopsies in cancer: opportunities and challenges
W.Yu1J.Hurley1D.Roberts1S.K.Chakrabortty1D.Enderle2M.Noerholm2X.O.Breakefield34J.K.Skog1
European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer
G.Carioli1M.Malvezzi1P.Bertuccio2P.Boffetta34F.Levi5C.La Vecchia1E.Negri2
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL☆
M.Martin123†C.Zielinski45†M.Ruiz-Borrego36E.Carrasco3N.Turner7E.M.Ciruelos38910M.Muñoz31112B.Bermejo231314M.Margeli315A.Anton2316Z.Kahan17T.Csöszi18M.I.Casas3L.Murillo319S.Morales320E.Alba2321E.Gal-Yam22A.Guerrero-Zotano323…M.Gil-Gil336
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆
C.Denkert12†M.Untch3†S.Benz4A.Schneeweiss5K.E.Weber6S.Schmatloch7C.Jackisch8H.P.Sinn910J.Golovato4T.Karn11F.Marmé12T.Link13J.Budczies2910V.Nekljudova6W.D.Schmitt2E.Stickeler14V.Müller15P.Jank12…S.Loibl620
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial☆
X.H.Wu1†J.Q.Zhu2†R.T.Yin3†J.X.Yang4J.H.Liu5J.Wang6L.Y.Wu7Z.L.Liu8Y.N.Gao9D.B.Wang10G.Lou11H.Y.Yang12Q.Zhou13B.H.Kong14Y.Huang15L.P.Chen16G.L.Li17R.F.An18…M.R.Mirza32
Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling
E.Ococks1†A.M.Frankell1†N.Masque Soler1†N.Grehan1A.Northrop1H.Coles1A.M.Redmond1G.Devonshire2J.M.J.Weaver1C.Hughes1K.Lehovsky1A.Blasko1B.Nutzinger1OCCAMS ConsortiumR.C.Fitzgerald1‡E.Smyth3‡
Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)☆
P.G.Casali12A.Le Cesne3A.P.Velasco4D.Kotasek5P.Rutkowski6P.Hohenberger7E.Fumagalli12I.R.Judson8A.Italiano8H.Gelderblom9N.Penel10J.T.Hartmann11†F.Duffaud12D.Goldstein13J.Martin-Broto14‡A.Gronchi1E.Wardelmann15S.Marréaud16…J.-Y.Blay18
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆
Y.Di Filippo1S.Dalle2L.Mortier3O.Dereure4S.Dalac5C.Dutriaux6M.-T.Leccia7D.Legoupil8P.Saiag9F.Brunet-Possenti10J.-P.Arnnault11E.Maubec12F.Granel-Brocard13J.De Quatrebarbes14F.Aubin15T.Lesimple16M.Beylot-Barry17P.-E.Stoebner18…H.Montaudié1
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial
H.-Y.Yhim12†T.Kim3†S.J.Kim4H.-J.Shin5Y.Koh6J.S.Kim7J.Park8G.S.Park9W.S.Kim4J.H.Moon10D.-H.Yang11
Access to essential anticancer medicines for children and adolescents in Europe
G.Vassal123O.Kozhaeva4S.Griskjane56F.Arnold7K.Nysom89L.Basset1011L.Kameric12A.Kienesberger13S.Kamal1415N.Cherny1617G.Bricalli17N.Latino17P.Kearns1819
Commentary: SARS-CoV-2 vaccines and cancer patients
C.Corti12G.Curigliano12
Multidisciplinary tumor boards as videoconferences – a new challenge in the COVID-19 era
M.W.Gross1H.Läubli2D.Cordier3
Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer
T.Bachelot1F.Dalenc2S.Chabaud3P.Cottu4D.Allouache5E.Brain6J-P.Jacquin7J.Grenier8L. VenatBouvet9M.Brunt10M.Campone11F.Del Piano12M.Debled13A-C. HardyBessard14S.Giacchetti15J.Bliss16J-L.Canon17J.Lemonnier18…F.André20
Retraction notice to “30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)�: [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428]
Y.Shi1L.Wu2X.Yu3P.Xing1J.Zhou4A.Wang5J.Shi6Y.Hu7Z.Wang8G.An9Y.Fang10S.Sun11C.Zhou12C.Wang13F.Ye14X.Li15J.Wang16M.Wang17…Y.Zhao19
Corrigendum to “Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy�: Annals of Oncology 2020; 31, suppl.4: S472 (abstr. 540P)
S.V.Liu1F.De Braud2A.Drilon3R.C.Doebele4M.R.Patel5B.C.Cho6M.J.Ahn7C.H.Chiu8A.F.Farago9K.Goto10J.Lee7Y.Ohe11S.H.I.Ou12P.Cassier13D.S.W.Tan14G.A.Otterson15L.Veronese16S.Osborne16…S.Siena1819
Corrigendum to “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer�: Annals of Oncology 2020; 31: 760-768
Y.Jiang12H.Wang2J.Wu2C.Chen3Q.Yuan3W.Huang1T.Li1S.Xi4Y.Hu1Z.Zhou5Y.Xu3G.Li1R.Li2
